This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2024 Sep 5;391(9):870-871.

doi: 10.1056/NEJMc2408733.

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply

Mark P Hamilton¹, David B Miklos¹, Ash A Alizadeh¹

Affiliations

PMID: 39231355
DOI: 10.1056/NEJMc2408733

Comment

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply

Mark P Hamilton et al. N Engl J Med. 2024.

. 2024 Sep 5;391(9):870-871.

doi: 10.1056/NEJMc2408733.

Authors

Mark P Hamilton¹, David B Miklos¹, Ash A Alizadeh¹

Affiliation

¹ Stanford University School of Medicine, Stanford, CA arasha@stanford.edu.

PMID: 39231355
DOI: 10.1056/NEJMc2408733

No abstract available

PubMed Disclaimer

Comment on

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S, Frank MJ, Sahaf B, Mackall CL, Gratzinger D, Diehn M, Alizadeh AA, Miklos DB. Hamilton MP, et al. N Engl J Med. 2024 Jun 13;390(22):2047-2060. doi: 10.1056/NEJMoa2401361. N Engl J Med. 2024. PMID: 38865660 Free PMC article.

Similar articles

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Godfrey J, Querfeld C, Song J. Godfrey J, et al. N Engl J Med. 2024 Sep 5;391(9):869-870. doi: 10.1056/NEJMc2408733. N Engl J Med. 2024. PMID: 39231354 No abstract available.
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S, Frank MJ, Sahaf B, Mackall CL, Gratzinger D, Diehn M, Alizadeh AA, Miklos DB. Hamilton MP, et al. N Engl J Med. 2024 Jun 13;390(22):2047-2060. doi: 10.1056/NEJMoa2401361. N Engl J Med. 2024. PMID: 38865660 Free PMC article.
T-Cell Neoplasms after B-Cell Neoplasms - The Pre-CAR T-Cell Era.
Dores GM, Morton LM. Dores GM, et al. N Engl J Med. 2024 Aug 15;391(7):662-664. doi: 10.1056/NEJMc2408029. N Engl J Med. 2024. PMID: 39141862 Free PMC article. No abstract available.
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
Wang N, Meng Y, Wu Y, He J, Liu F. Wang N, et al. Immunotherapy. 2021 Mar;13(4):345-357. doi: 10.2217/imt-2020-0221. Epub 2021 Jan 7. Immunotherapy. 2021. PMID: 33406914
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P, Neelapu SS. Strati P, et al. Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z. Curr Oncol Rep. 2019. PMID: 30919158 Review.

See all similar articles

Cited by

Drug-induced second tumors: a disproportionality analysis of the FAERS database.
Chen S, Zhang Y, Li X, Tang N, Zeng Y. Chen S, et al. Discov Oncol. 2025 May 16;16(1):786. doi: 10.1007/s12672-025-02502-6. Discov Oncol. 2025. PMID: 40377769 Free PMC article.
Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy.
Ottaviano G, Qasim W. Ottaviano G, et al. Leukemia. 2025 Jun;39(6):1325-1333. doi: 10.1038/s41375-025-02585-8. Epub 2025 Apr 8. Leukemia. 2025. PMID: 40200078 Free PMC article. Review.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.